Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer - Azar, Ibrahim; Alkassis, Samer; Fukui, Jami; Alsawah, Fares; Fedak, Kalub; Al Hallak, Mohammed Najeeb; Sukari, Ammar; Nagasaka, Misako (Lung Cancer: Targets and Therapy, 2021)
Keywords: antibody drug conjugate; Antitumor agents; Biological products; Breast cancer; Cancer; Care and treatment; Cell growth; Clinical trials; DNA topoisomerase; Drug approval; ds8201; Epidermal growth factor; ErbB-2 protein; FDA approval; Gastric cancer; Genetic aspects; Health aspects; her2; Immunotherapy; Kinases; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Monoclonal antibodies; Mutation; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Non-small cell lung carcinoma; Pertuzumab; Pharmaceutical industry; Pharmacodynamics; Pharmacokinetics; Protein-tyrosine kinase; RC254-282; Review; Small cell lung carcinoma; Stomach cancer; t-dxd; Targeted cancer therapy; Targets and Therapy [Lung Cancer]; Trastuzumab; Tumorigenesis; Tyrosine; United States